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Guanidino Compounds in Guanidinoacetate Methyltransferase Deficiency, a New 
Inborn Error of Creatine Synthesis
S. Stockier, B. Marescau, P.P. De Deyn, J.M.F. Trijbels, and F. Hanefeld
The first inborn error of creatine metabolism (guanidinoacetate methyltransferase [GAMT] deficiency) has recently been 
recognized in an infant with progressive extrapyramidal movement disorder. The diagnosis was established by creatine 
deficiency in the brain as detected by in vivo magnetic resonance spectroscopy and by defective GAMT activity and two 
mutant GAMT alleles in a liver biopsy. Here, we describe characteristic guanidino-compound patterns in body fluids of this 
index patient with GAMT deficiency. Concentrations of guanidino compounds (creatine and guanidinoacetate) and creatinine 
were determined by cation-exchange chromatography and by color reaction with picric acid, respectively, in urine, plasma, and 
cerebrospinal fluid (CSF). Creatine concentrations were low in plasma, CSF, and urine while guanidinoacetate concentrations 
were markedly elevated. Daily urinary creatinine excretion was low, whereas creatinine concentrations in random urine 
samples were not always discriminative. Guanidino compound to creatinine ratios were not informative, as low creatinine 
concentrations resulted in high values for all determined compounds. During a 22-month period of oral treatment with 
creatine-monohydrate, plasma and urinary creatine concentrations increased to levels high above the normal range, and daily 
urinary creatinine excretion—proportional to total body creatine—became normalized. Guanidinoacetate concentrations 
remained elevated even during additional substitution of ornithine, which inhibits guanidinoacetate synthesis in vitro. The 
results indicate that GAMT deficiency can be recognized noninvasively by determination of guanidino compounds (creatine 
and guanidinoacetate) in body fluids. A deficiency of creatine, but not an accumulation of guanidinoacetate, can be corrected 
by treatment with oral creatine substitution.
Copyright © 1997 by W.B, Saunders Company
IN  HUMANS, creatine is synthesized in the liver and pancreas, 1 involving arginine:glycine amidinotransferase 
and guanidinoacetate methyltransferase ([GAMT] EC 2.1.1.2) 
as enzymes. GAMT catalyzes the final step in the biosynthesis 
of creatine by transferring a methyl group from S-adenosyl- 
methionine to guanidinoacetate.2 Creatine is used in muscle and 
nerve tissue, where the pool of creatine/creatine phosphate 
together with creatine kinase and adenosine triphosphate/ 
monophosphate play an important role in the storage and 
transmission o f  phosphate-bound energy. Creatine is converted 
by nonenzymatic cyclization to creatinine, with a daily turnover 
of 1.5% of body creatine.3 For maintenance of the body pool, 1 
to 2 g (7.6 to 15.2 mmol) creatine— equivalent to the daily 
urinary excretion o f  creatinine— must be provided from endog­
enous synthesis or from dietary sources.1
GAMT deficiency is the first inborn error o f  creatine 
synthesis in man, and its clinical4 and molecular5 features, as 
well as the favorable response to oral creatine replacement 
therapy,6 have recently been described in the first patient with 
this disorder. Here, we report characteristic guanidino- 
compound (creatine and guanidinoacetate) and creatinine pat­
terns in the body fluids from this same patient diagnosed with 
GAMT deficiency.
SUBJECTS AND METHODS
Urine, plasma, and cerebrospinal fluid (CSF) were available from a
male infant with GAMT deficiency. Samples obtained before treatment
with creatine monohydrate were evaluated at ages 14 and 22 months. In
addition, samples obtained during a 22-month course of treatment with
h
creatine monohydrate (4 and 8 g/d) and during a 12-week period of 
additional substitution with ornithine I-IC1 (8 g/d) were evaluated. Both 
substances were administered orally in eight single doses with 2~hour 
intervals between 6 a m  and 10 p m , and with an 8-hour interval between 
10 pm and 6 a m . Details about the clinical features of the patient and the 
favorable clinical response to creatine substitution have been described 
elsewhere.4,6
Determination of Metabolites in Urine, Plasma, and CSF
Creatine, guanidinoacetate, and other guanidino-compounds were 
assayed using a Biotronic LC 5001 (Biotronic, Maintal, Germany) 
amino acid analyzer adapted for guanidino-compound determination. 
Guanidino compounds were separated over a cation-exchange column 
using sodium citrate buffers, and were detected with the fluorescence 
ninhydrin method as previously reported in detail,7
Serum and urinary creatinine were determined using a Beckman 2 
(Irvine, CA) creatinine analyzer by a color reaction with picric acid. 
With this method, there was no unspecific reaction with standard 
solutions of guanidinoacetate or creatine.
Plasma ornithine concentrations were measured by ion-exchange 
chromatography on a Biotronic LC3000 amino acid analyzer.
RESULTS
Guanidino Compounds in Plasma, CSF, and Urine Before 
Treatment With Creatine Monohydrate
In plasma, the most pronounced findings were extremely low  
concentrations o f  creatine and creatinine and extremely high  
concentrations of guanidinoacetate, with values more than 
10-fold higher than normal. Homoarginine was constantly 
increased, besides various less pronounced abnormalities, includ­
ing low arginine and high 7 -guanldinobutyrate concentrations, 
The abnormal plasma patterns were also reflected in CSF; 
however, for guanidinoacetate and creatine, the abnormalities in 
CSF were even more pronounced, with values more than
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100-fold higher (guanidinoacetate) or lower (creatine) than 
normal. In random urine samples, an extremely high guanidino­
acetate concentration (2,224 to 3,987 ^mol/L; normal, 63.4 to 
429) was the most specific abnormality, whereas creatine 
concentrations were within the low-normal range (56.9 to 106 
jumo3/L; normal, 46 to 5,250). Due to consistently low urinary 
creatinine concentrations (1,060 to 2,060 [itnol/L; normal, 1,800 
►
to 4,400), guanidino-compound/creatinine ratios were unspecifi- 
cally high for all measured metabolites (Table 1).
Guanidino C om pounds in P lasm a  a n d  Urine D uring Treatment 
With Creatine M onohydra te  a n d  Ornithine H C l
As a consequence o f  GAMT deficiency, endogenous synthe­
sis of creatine is defective. On the assumption that exogenous 
(intes tin ally absorbed) creatine is not degraded in the liver and 
is as accessible to muscle and brain as the endogenous 
compound, we began oral replacement therapy at age 23 months 
with creatine monohydrate 4 g/d (305 to 370 mg/kg body 
weight/d) and doubled the creatine monohydrate dose (8 g/d, 
600 to 640 mg/kg body weight/d) at age 35 months.
Plasma creatine concentrations increased from low (0.39 to 
1.24 |jmol/L; normal, 86.9 ±  18.5) to extremely high (270 to 
763 pmol/L) values, indicating sufficient intestinal absorption 
of creatine monohydrate (Fig 1). The increase of plasma 
creatine was paralleled by normalization o f  low plasma creati­
nine concentrations (plasma creatinine before treatment, 7
*
pmol/L [0.08 mg/dL]; during treatment, 35.4 |jmol/L [0.4 
mg/dL]; normal,8 17.7 to 35.4 [0.2 to 0.4]). Guanidinoacetate 
decreased gradually from 12,9 to 25.7 (jmol/L to 5.76 to 4*32 
|umol/L, but values remained increased at all times (normal, 
0,832 ±  0.315) (Fig 1). The increased homoarginine concentra­
tions (2.43 to 3.73 jumol/L) also decreased (minimum, 1.21 to 
1.48 pmol/L), but also did not return to normal (normal,
0.66 ±  0.18). These patterns were not changed when the 
creatine monohydrate dose was doubled,
After 4 weeks of therapy, the low urinary creatinine excretion 
(8.9 to 12.4 jjmol [1.0 to 1.4 mg]/kg body weight/d; normal ,y 71 
to 177 [8 to 20]/kg body weight/d) normalized (147 pmol [16.6 
mg]/kg body weight/d), indicating restoration of the body 
creatine pool (Fig 2A). Simultaneously, urinary creatine in­
creased to values far above the upper-normal range (65,613 to 
111,810 |jmol/L), indicating renal overflow due to high-dose 
oral creatine substitution. Urinary guanidinoacetate concentra­
tions decreased gradually from extremely high values (2,224 to 
3,987 (jitioVL) before creatine substitution to lower but still 
elevated values (1,120 jumol/L; normal, 63.4 to 429) (Fig 2B).
On the rationale that guanidinoacetate synthesis should be 
reduced by inhibition of arginine:glycine amidinotransferase 
with high-dose ornithine, 10 a 12 -week trial (42 to 45 months of 
age) with additional substitution of ornithine HCl (8 g/d, 600 to 
640 mg/kg/body weight/d) was performed. Plasma ornithine 
concentrations increased from 74 to 89 jimol/L before ornithine 
substitution to 250 to 400 fimol/L during ornithine substitution 
(normal, 10 to 163), but there was no parallel decrease in plasma (Fig 
1 ) and urinary (Fig 2B) guanidinoacetate concentrations.
DISCUSSION
GAMT deficiency results in defective endogenous creatine 
biosynthesis with depletion of body creatine and accumulation 
of guanidinoacetate, which is a substrate to the defective 
enzyme. Accordingly, in this first patient with GAMT defi­
ciency, high concentrations of guanidinoacetate and low concen­
trations o f  creatine were characteristic findings in urine, plasma, 
and CSF. In addition, daily (24-hour) urinary creatinine excre­
tion was extremely low, reflecting depletion of the body creatine 
pool. Creatinine excretion is directly related to body creatine, 11 
and assessment of it in 24-hour urine may be helpful in the 
diagnosis o f  defects in creatine biosynthesis. However, this test 
may not be reliable in newborns and very young infants, since 
animal experiments indicate that the maternal intrauterine
Table 1. Guanidino-Compound Levels in a Patient With GAMT Deficiency Before Treatment With Creatine Monohydrate in Plasma (jxmol/L),
CSF {(xmol/L), and Random Urine Samples {^.mol/g creatinine; jjumol/L)
Urine
Plasma CSF Patient
Guanidino
Patient Control Patient Control 14 Mo 22 Mo Control (n = 17)
Compound 14 Mo 22 Mo (n = 17) 11 Mo 22 Mo (n = 15) pmol/g pmol/L pmol/g gmol/L pmol/g pmol/L
a-K-5'GVA <0.035 0.07 <0.035-0.215 <0.018 <0.018 <0.018-0.050 40.2 5.63 26.1 7,04 <DL-40 <DL-10
GSA 0.150 0,230 0.283 ± 0.136 0.150 0.150 0.052 ± 0.022 266 37.3 231 62.4 24-120 2.90-27.3
CT 0.39 1,24 86.9 ± 18.5 0.280 0.530 38.8 ± 4.76 407.0 56.9 394 106 250-15,000 46-5,250
GAA 12.9 20.7 0.832 ± 0.315 10.6 12.7 0,055 ± 0.032 15,889 2,224 14,767 3,987 400-1,600 63.4-429
a-N-AA <0.015 <0.015 <0.019-0.270 <0.007 <0.007 <0.007-0,045 212 29.7 535 117 18-70 3.16-14,1
ArgA <0.015 <0.070 <0,019-0,068 <0.007 <0.007 <0.007-0.035 53.7 7.52 94.4 25.5 4-30 0.440-7.81
ß-GPA <0.013 <0.013 <0.013 <0.007 <0.007 <0.007 14.0 1.96 3.96 1.07 <DL <DL
CTN 5.21 3.33 20.2 ± 7.49 <1.0 <1.0 34.9 ± 5.59 1,060 2,060 1,800-4,400
"y-GBA 0.080 0.050 <0.019 0.080 0.050 <0.006-0.065 594 83.2 486 131 15-60 2.65-10,7
Arg 19.1 43.9 97.5 ± 26.6 11.4 16.9 21.3 ±4.37 255 35.7 302 81.5 20-120 3.64-20.6
HArg 2.43 3,73 0.660 ± 0.178 0.800 0.640 0.205 ± 0.072 19.8 2.77 46.3 12.5 <DL-15 <DL-3.42
G 0.260 0.160 <0.200-0.390 <0.030 0.060 <0.030-0.100 175 24.5 90.7 24.5 10-90 2,17-17.4
MG <0.02 <0.02 <0.06 <0.010 <0.010 <0.010 9.7 1.36 8.93 2.41 <DL-10 <DL-3,33
NOTE. Plasma and urine samples were taken at ages 14 and 22 months; CSF samples were obtained at 11 and 22 months. Normal values were 
obtained from respective samples of age-matched controls.
Abbreviations: a-K-S-GVA, a-K-S-guanidinovalerate; GSA, guanidinosuccinate; CT, creatine; GAA, guanidinoacetate; a-N-AA, u-A/- 
acetylarginine; ArgA, argininic acid; (3-GPA, (3-guanidino propionate; CTN, creatinine; y-GBA, 7-guanidinobutyrate; Arg, arginine; HArg, 
homoarginine; G, guanidine; MG, methylguanidine; DL, detectable limit.
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Fig 1. Plasma concentrations of creatine {•), guanidinoacetate (□), and homoarginine (o) in a patient with GAMT deficiency before treatment 
with creatine monohydrate (samples taken at 14, 22, and 23 months of age) and during a 22-month time course (23 to 46 months of age) of 
treatment with creatine monohydrate (4 and 8 g/d). Ornithine HCl was additionally substituted between 42 and 45 months of age. Normal range: 
creatine, 86.9 ± 18.5 n,mol/L; guanidinoacetate, 0.832 ± 0.315 |u,mol/L; homoarginine, 0.660 ± 0.178 |xmol/L
creatine supply12 provides the newborn with a full creatine pool, 
and depletion will follow a slow process with a daily reduction 
of the creatine pool equal to 1.5% of creatine turnover.3
In random urine samples, an elevated guanidinoacetate 
concentration was specific. Calculation of guanidino-compound 
to creatinine ratios showed elevated values for all metabolites. 
These artificially high ratios are explained by the fact that in 
primary creatine deficiency, creatinine excretion is consistently 
low independently o f  the concentration of the renal urinary 
filtrate. Therefore, determination of urinary guanidino com­
pounds, especially when related to urinary creatinine concentra­
tions, are less informative than the concentrations measured in 
plasma and CSF,
Oral substitution of creatine monohydrate resulted in a 
marked increase of plasma creatine concentrations. Final plasma 
creatine concentrations were markedly higher than normal, with 
peak values 1 hour after oral creatine administration. The high 
plasma creatine concentrations and normalization o f  plasma and 
urinary creatinine concentrations clearly indicate that substi­
tuted creatine was sufficiently absorbed in the intestine and 
regularly metabolized by muscle and brain, the major sites o f  
creatine utilization.
Guanidinoacetate is synthesized from arginine and glycine by 
the activity of arginine:glycine amidinotransferase, the regulat­
ing enzyme of creatine biosynthesis. The gene expression of  
this enzyme is mainly controlled by a creatine-dependent 
negative-feedback mechanism .13 In our patient, repression of  
(highly expressed) arginine:glycine amidinotransferase activity 
by exogenous creatine led to a decrease but not normalization of
guanidinoacetate concentrations in body fluids. Further reduc­
tion o f  guanidinoacetate concentrations via competitive inhibi­
tion o f  arginine:glycine amidinotransferase activity by addi­
tional substitution with high-dose ornithine10 failed. The 
persistence o f  guanidinoacetate accumulation despite normaliza­
tion o f  body creatine is explained by the block in the main 
metabolic pathway of guanidinoacetate caused by defective 
GAM T activity. The parallel changes of plasma guanidinoac­
etate and homoarginine levels during therapeutic follow-up 
evaluation confirm previous in vitro studies showing that both 
homoarginine and guanidinoacetate are synthesized by kidney 
L-arginine:glycine amidinotransferase. 14
The extremely high guanidinoacetate concentrations in CSF, 
exceeding normal values by a factor of 200 , deserve special 
attention. CSF concentrations of guanidinoacetate were approxi­
mately the same as the respective plasma values, indicating free 
passage of guanidinoacetate across the blood-brain barrier. In 
normal individuals, guanidinoacetate concentrations are signifi­
cantly lower in CSF than in plasma, suggesting immediate 
metabolism of guanidinoacetate after its passage across the 
blood-brain barrier. Immediate metabolism of guanidinoacetate 
may be effected by its conversion to creatine via cerebral 
(neuronal) GAMT activity, which has already been proposed in 
experimental studies. 15,16 Accordingly, in this patient with 
GAMT deficiency, defective cerebral enzyme activity explains 
the observed severe accumulation of guanidinoacetate in C SF  
Our patient improved drastically on oral creatine substitution,6 
but neurologic symptoms were not completely reversible, 
despite normalization o f  the cerebral creatine pool. One reason
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Fig 2. Daily urinary excretion of creatinine (■) as a measure of total body creatine and IB) urinary concentrations of creatine {•) and 
guanidinoacetate (D) in a patient with GAMT deficiency. Samples were taken before treatment with creatine monohydrate (at 14, 22, and 23 
months of age) and during a 22-month time course of treatment with creatine monohydrate (4 and 8 g/d, 24 to 46 months of age). Normal range: 
daily urinary creatinine excretion, 71 to 177 jjumol/kg body weight/d)9; urinary creatine, 46 to 5,250 ^mol/L; urinary guanidinoacetate, 63.4 to 429 
jjumol/L.
for the incomplete reversal o f  neurologic symptoms during 
creatine replacement therapy seems to be the accumulation of  
guanidinoacetate, which is neurotoxic in high concentrations.17 
Another reason may be irreversible brain damage acquired 
before creatine substitution therapy.
The improvement of biochemical and clinical symptoms 
during oral substitution o f  creatine is an indication that GAMT 
deficiency is a treatable disorder. Therefore, the development o f
simple screening methods for early detection is of major 
importance. As shown in this index patient, accumulation o f  
guanidinoacetate is highly specific for GAMT deficiency, and 
routine determination of this compound should become possible 
by chromatography,7’ 18 color reaction,m o  or gas chromato­
graphic/mass spectrometric methods.21 The experience in this 
index patient suggests that plasma and CSF are the best 
biological samples to be investigated.
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